Which one of the statements is false regarding adefovir dipivoxil?
Nonselective antiviral drugs: Ribavirin, Lamivudine, Adefovir dipivoxil, Interferon alpha. Adefovir dipivoxil It is the diester prodrug of AMP analogue adefovir which is active against hepatitis B virus (HBV) and some other DNA viruses. Esterases in the intestine and liver release the active drug during absorption to attain oral bioavailability of -60% in terms of adefovir, which is then distributed in whole body water. On entering cells, adefovir (a monophosphate) is phosphorylated to the diphosphate which has high affinity for HBV DNA polymerase. This enzyme is inhibited and adefovir itself gets incorporated in the viral DNA resulting in termination of the DNA chain. While plasma half life of adefovir is -7 hours (due to renal excretion), intracellular half life of the diphosphate is upto 18 hours. Adefovir is indicated in chronic hepatitis B, including lamivudine-resistant cases and those having concurrent HlV infection. There is no cross resistance between adefovir and lamivudine. Clinical, biochemical (liver function tests), histological, serological and virological response occurs in nearly 50% patients within 1 year. More cases respond with continued treatment. The optimum duration of treatment is unceain at present. At 10 mg/ day dose adefovir is well tolerated. Side effects are sore throat, headache, weakness, abdominal pain and flu syndrome. Nephrotoxicity occurs at higher doses and in those with preexisting renal insufficiency. Lactic acidosis is a risk in patients receiving anti-HIV drugs ESSENTIALS OF MEDICAL PHARMACOLOGY K.D.TRIPATHI SIXTH EDITION PAGE NO:778
Acyclic nucleotide analogue
Well tolerated orally
Used in chronic hepatitis B infection
Used in anti-retroviral therapy
Chemotherapy